Rilmenidine
Rilmenidine (I1-imidazoline receptor agonist antihypertensive)
Written by Aaron CuhaReviewed Sep 2026
Also known as: Hyperium, Tenaxum, Albarel, Iterium
A European blood pressure drug that extends lifespan in Caenorhabditis elegans through the nischarin receptor. In mammals the record is worse than neutral: it induced autophagy as designed in two mouse models of motor neuron disease and made both of them worse.
Overview
Rilmenidine is a centrally acting antihypertensive that works through the I1-imidazoline receptor. It entered geroscience sideways, through a screen for compounds whose gene expression signature resembles caloric restriction, and it came out near the top.
In C. elegans it increases lifespan when started young and when started in older worms, and the effect depends on the I1-imidazoline receptor nish-1, on the transcription factors DAF-16 and SKN-1, and on autophagy. It did not add anything on top of caloric restriction, reduced TORC1 signalling or rapamycin, which is consistent with it acting through the same pathway rather than a new one. The same paper reported caloric-restriction-like transcriptional changes in the liver and kidney of treated mice, which is a gene expression result and not a survival result.
The mammalian record on hard endpoints is the part that rarely gets quoted. Rilmenidine was picked up years earlier by the autophagy field as a safer alternative to rapamycin for clearing aggregated proteins, and it did attenuate disease signs in a Huntington's disease mouse model. Then it was tested in two models of motor neuron disease. In SOD1G93A mice it induced autophagy and mitophagy robustly and worsened motor neuron degeneration and symptom progression. In TDP-43 transgenic mice it truncated lifespan, accelerated motor neuron loss and cleared TDP-43 from nuclei.
The one human study was an 18 patient open-label safety and feasibility trial in Huntington's disease. It was not designed to test efficacy and did not report any.
Mechanism of action
Agonist at the I1-imidazoline receptor, with weaker alpha-2 adrenoceptor activity than clonidine, which is why it lowers blood pressure with less sedation. The geroscience mechanism proposed is induction of mTOR-independent autophagy plus a transcriptional state resembling caloric restriction. In the worm the longevity effect requires the nischarin I1-imidazoline receptor nish-1, the FOXO orthologue DAF-16, the NRF orthologue SKN-1 and intact autophagy, and notably does not require AMPK signalling. The mouse neurodegeneration work is the cautionary half of the same mechanism: the autophagy and mitophagy induction is real and measurable, and in those models excessive mitochondrial clearance in motor neurons appears to be what causes the harm.
Human evidence
Decades of use as a blood pressure drug in the markets where it is licensed, and one 18 patient open-label study in Huntington's disease. Nothing in humans on ageing.
- Licensed antihypertensive in France and several other European markets, with the ordinary post-marketing safety record that implies.
- One 2 year open-label study in 18 people with Huntington's disease, designed to test tolerability rather than efficacy, with 12 completers and no efficacy claim made.
- No human trial has measured lifespan, healthspan, biological age or any ageing biomarker with rilmenidine.
- The mouse data on hard endpoints is negative twice over, in SOD1 and TDP-43 models of motor neuron disease, where the drug did what it was supposed to do mechanistically and the animals did worse.
What this does not tell you: A worm is not a mammal, and the mouse work in this compound is the reason that sentence matters here. The Aging Cell mouse data is a transcriptional signature in liver and kidney, not survival. The only mouse survival data that exists for rilmenidine is the shortened lifespan in the TDP-43 model. Nobody has run a mouse lifespan study of rilmenidine in normal ageing.
Reading the research record
There are two separate evidence questions about any repurposed drug and they have different answers. The first is whether the drug does what it was licensed to do, which here is settled by randomised trials with hard clinical endpoints. The second is whether it slows ageing in humans, which no trial has tested. The strength of the first answer says nothing about the second. A reader who takes the licensed indication as partial proof of the ageing claim has made the central error of this field.
Rilmenidine is the clearest case here of the gap between a mechanism working and an animal benefiting. Two independent mouse experiments showed that the drug induces autophagy and mitophagy exactly as advertised, measured directly in spinal cord tissue, and that the treated animals then deteriorated faster than controls. In one of them the reported harm included a truncated lifespan. That is not a tolerability signal, it is evidence that this particular intervention is context dependent in a way the worm data cannot reveal.
The honest summary is that rilmenidine has a genuinely interesting invertebrate longevity result with a defined receptor, a plausible caloric restriction mimetic signature in mouse tissue, no mammalian lifespan study in normal ageing, and two mammalian studies in disease models where it caused harm. The autophagy induction is the selling point and it is also the mechanism the authors blame for the damage.
The evidence, charted
Fig. 1 · evidence composition
1of 5 citations (20%) are in people
Counted from the citation list on this page. The Human count is the same number shown in the badge at the top. Both understate any literature larger than the sources we cite.
Fig. 2 · evidence over time
Evidence spans 5 distinct years, 2010 to 2023, counted from the citation list on this page.
Fig. 3 · legal status at a glance
US
Not approved
UK
Not approved
AU
Not approved
CA
Not approved
Not approved in any of the four jurisdictions shown. A jurisdiction's classification is a regulatory fact, not a verdict on the science; see Legal status below for the full text and any notes.
Fig. 4 · dose response
No human dose response curve exists
We draw this figure where the data supports it. For this compound in humans it does not, so the panel stays empty rather than borrowing an animal curve and implying it transfers.
Key studies & citations
- Animal2023
Rilmenidine extends lifespan and healthspan in Caenorhabditis elegans via a nischarin I1-imidazoline receptor
The paper that put rilmenidine into geroscience. Identified by searching for compounds with a caloric-restriction-like expression signature. Increased lifespan in C. elegans when given at young and older ages, with the stress resilience, healthspan and lifespan benefits all dependent on the I1-imidazoline receptor nish-1, on DAF-16 and SKN-1, and on autophagy but not AMPK. Adding it to calorically restricted worms, reduced TORC1 function or rapamycin produced no further gain. Mice treated with rilmenidine showed caloric-restriction-like transcriptional changes in liver and kidney, which is a gene expression finding and not a lifespan finding. Two authors disclose commercial longevity interests.
Aging Cell - Animal2010
Rilmenidine attenuates toxicity of polyglutamine expansions in a mouse model of Huntington's disease
The result that made rilmenidine interesting to the autophagy field. It was found in a screen of approved drugs for mTOR-independent autophagy induction, induced autophagy in mice and in primary neuronal culture, attenuated disease signs in a Huntington's disease mouse model and reduced levels of the mutant huntingtin fragment.
Human Molecular Genetics - Animal2018
Rilmenidine promotes MTOR-independent autophagy in the mutant SOD1 mouse model of amyotrophic lateral sclerosis without slowing disease progression
Autophagy and mitophagy were induced in the spinal cord as intended and soluble mutant SOD1 fell, and despite that rilmenidine worsened motor neuron degeneration and symptom progression in SOD1G93A mice. The authors attribute the harm to excessive mitophagy and severe mitochondrial depletion in motor neurons.
Autophagy - Animal2021
Stimulation of mTOR-independent autophagy and mitophagy by rilmenidine exacerbates the phenotype of transgenic TDP-43 mice
The second and harder negative. In TDP-43WTxQ331K double transgenic mice, rilmenidine induced robust spinal cord autophagy and exacerbated the phenotype: truncated lifespan, accelerated motor neuron loss and pronounced clearance of TDP-43 from nuclei. A lifespan result in mice pointing the wrong way.
Neurobiology of Disease - Human2017
An open-label study to assess the feasibility and tolerability of rilmenidine for the treatment of Huntington's disease
The only sustained human study in a neurological population. 18 non-demented patients with mild to moderate Huntington's disease took 1 mg daily for 6 months then 2 mg for a further 18 months. 12 completed. Three serious adverse events were recorded including hospitalisation for depression, none judged drug related. The primary outcome was withdrawals and serious adverse events, not efficacy, and the authors state that changes in secondary outcomes were comparable to untreated observational cohorts without formal statistical comparison.
Journal of Neurology
Frequently asked questions
Does rilmenidine extend lifespan?
In C. elegans, yes, when started young or in older worms, through the nischarin I1-imidazoline receptor. In mice there is no lifespan study in normal ageing at all. The only mouse lifespan number that exists for this drug is a shortened lifespan in a TDP-43 model of motor neuron disease. There is no human data on ageing.
Is it a caloric restriction mimetic?
It was found by searching for that signature, and treated mice show caloric-restriction-like transcriptional changes in liver and kidney. In worms it produced no additional lifespan on top of caloric restriction, reduced TORC1 or rapamycin, which is what you would expect if it acts through the same pathway rather than a separate one.
Is it safer than rapamycin?
It was pursued precisely because it was thought to be, and that assumption is exactly what the motor neuron disease work undermines. As a blood pressure drug it has a long ordinary safety record in the countries where it is licensed. As an autophagy inducer it made two mouse neurodegeneration models worse, which rapamycin comparisons rarely mention.
Can I get it in the United States?
It has no FDA approval, so no. It is a licensed medicine in France and several other European markets, which is why it circulates through personal import. That route means no prescriber monitoring blood pressure on a centrally acting antihypertensive, which is the practical risk rather than a theoretical one.
What dose did the human study use?
The Huntington's disease study used 1 mg daily for 6 months then 2 mg daily for 18 months, which is the ordinary antihypertensive dose range. That study measured whether people could tolerate the drug, not whether it helped, and made no efficacy claim.